# Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2

> **NCT03306836** · NA · UNKNOWN · sponsor: **Beijing Tiantan Hospital** · enrollment: 408 (estimated)

## Conditions studied

- Cerebral Aneurysm
- Arteriovenous Malformations

## Interventions

- **DRUG:** Heparin Sodium
- **DRUG:** Heparin Sodium

## Key facts

- **NCT ID:** NCT03306836
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2020-09
- **Final completion:** 2021-08
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2017-10-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03306836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03306836, "Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03306836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*